Skip to content
Riskpilot
← Back to search
Sign in
Get full access
LIPLASOME PHARMA ApS
APS
Active
Advertising protection
CVR 29428514
Tabletvej 1, 7100
Vejle
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2006 · 20 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
LIPLASOME PHARMA ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
1M
1M
2M
2M
0M
2021
2M
2022
0M
2023
0M
2024
0M
2025
EBITDA
DKK millions
3M
2M
1M
1M
0M
0M
2021
2M
+200%
2022
0M
-100%
2023
0M
0%
2024
0M
0%
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Gross profit
108
2.202
-29
-53
-28
Staff expenses
-0
-0
-0
-0
-0
EBITDA
108
2.202
-29
-53
-28
Depreciation & amort.
-0
-0
-0
-0
-0
EBIT
108
2.202
-29
-53
-28
Net financials
-10
-6
3
7
90
Profit before tax
98
2.196
-26
-46
62
Tax
-0
-0
-6
-10
-0
Net profit
98
2.196
-20
-36
62
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
186
2.383
2.363
2.330
2.389
Equity
175
2.371
2.351
2.315
2.377
Long-term debt
0
0
0
0
0
Short-term debt
11
12
12
15
12
Total debt
11
12
12
15
12
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-2800000.0%
This company
2021
2025
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
2021
2025
Return on equity
2.6%
This company
18.4%
Market median
-86% vs market
2021
2025
Net profit margin (of gross profit)
6200000.0%
This company
2021
2025
Asset turnover (of gross profit)
-0.01×
This company
2021
2025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on LIPLASOME PHARMA ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
